Kenichiro Watanabe

Kenichiro Watanabe

Auto-generated profile, based on publicly available information

Kenichiro Watanabe

Department of Hematology and Oncology Shizuoka Children's Hospital Shizuoka Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
MYMasahide Yamamoto
Masahide Yamamoto
MSMaho Sato
Maho Sato
YOYasushi Onishi
Yasushi Onishi
YSYoji Sasahara
Yoji Sasahara
HSHideki Sano
Hideki Sano
Ayako AraiAyako Arai
Ayako Arai

22 May 2025 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
Luca PioLuca Pio
Luca Pio
AOAllison F. O’nEill
Allison F. O’nEill
HWHelen Woodley
Helen Woodley
AMAndrew Murphy
Andrew Murphy
GTGregory Tiao
Gregory Tiao
SBSophie Branchereau
Sophie Branchereau

20 September 2013 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
KWKenichiro Watanabe
Kenichiro Watanabe

28 December 2018 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
KWKenichiro Watanabe
Kenichiro Watanabe

20 June 2024 in Blood
Verified
Journal Article
Closed access
PDF file
TSTomohiko Sato
Tomohiko Sato
KYKenichi Yoshida
Kenichi Yoshida
TTTsutomu Toki
Tsutomu Toki
RKRika Kanezaki
Rika Kanezaki
KTKiminori Terui
Kiminori Terui
EIEtsuro Ito
Etsuro Ito
Transient abnormal myelopoiesis (TAM) is a common complication in newborns with Down syndrome (DS). It commonly progresses to myeloid leukemia (ML-DS) after spontaneous regression. In contrast to the favorable prognosis of primary ML-DS, patients with refractory/relapsed ML-DS have poor outcomes. However, the molecular basis for refractoriness and relapse and the full spectrum of driver mutations in ML-DS remain largely unknown. We conducted a genomic profiling study of 143 TAM, 204 ML-DS, and 34 non-DS acute megakaryoblastic leukemia cases, including 39 ML-DS cases analyzed by exome sequencing. Sixteen novel mutational targets were identified in ML-DS samples. Of these, inactivations of IRX1 (16.2%) and ZBTB7A (13.2%) were commonly implicated in the upregulation of the MYC pathway and were potential targets for ML-DS treatment with bromodomain-containing protein 4 inhibitors. Partial tandem duplications of RUNX1 on chromosome 21 were also found, specifically in ML-DS samples (13.7%), presenting its essential role in DS leukemia progression. Finally, in 177 patients with ML-DS treated following the same ML-DS protocol (the Japanese Pediatric Leukemia and Lymphoma Study Group acute myeloid leukemia -D05/D11), CDKN2A, TP53, ZBTB7A, and JAK2 alterations were associated with a poor prognosis. Patients with CDKN2A deletions (n = 7) or TP53 mutations (n = 4) had substantially lower 3-year event-free survival (28.6% vs 90.5%; P < .001; 25.0% vs 89.5%; P < .001) than those without these mutations. These findings considerably change the mutational landscape of ML-DS, provide new insights into the mechanisms of progression from TAM to ML-DS, and help identify new therapeutic targets and strategies for ML-DS.

10 February 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
MKMotohiro Kato
Motohiro Kato
YOYasuhiro Okamoto
Yasuhiro Okamoto
TIToshihiko Imamura
Toshihiko Imamura
AKAkiko Kada
Akiko Kada
ASAkiko M. Saito
Akiko M. Saito
KKKatsuyoshi Koh
Katsuyoshi Koh
PURPOSE: The JCCG ALL-B12 clinical trial aimed to evaluate the effectiveness of unvalidated treatment phases for pediatric ALL and develop a safety-focused treatment framework. PATIENTS AND METHODS: Patients age 1-19 years with newly diagnosed B-ALL were enrolled in this study. These patients were stratified into standard-risk (SR), intermediate-risk (IR), and high-risk (HR) groups. Randomized comparisons assessed the effectiveness of vincristine (VCR)/dexamethasone pulses in the SR group, evaluated the effects of L-asparaginase (ASP) intensification in the IR group, and compared standard consolidation including block-type treatment with experimental consolidation with high-dose methotrexate (HD-MTX) intensified with VCR and ASP in the HR group. RESULTS: Of 1,936 patients enrolled, 1,804 were eligible for the experimental treatment. The overall 5-year event-free survival and overall survival rates were 85.2% (95% CI, 83.5 to 86.8) and 94.3% (95% CI, 93.1 to 95.3), respectively. The cumulative incidence of relapse and postremission nonrelapse mortality was 13.2% (95% CI, 11.6 to 14.8) and 0.6% (95% CI, 0.3 to 1.0), respectively. Random assignment in the SR group showed no significant benefit from pulse therapy. In the IR group, ASP intensification had limited effects. In the HR group, standard block therapy and HD-MTX yielded equivalent outcomes. CONCLUSION: The ALL-B12 trial achieved favorable outcomes in a nationwide cohort by stratifying treatment on the basis of risk and balancing treatment intensity. This study not only demonstrated that existing standard of care can be further refined but also indicated that improvement in outcomes with intensified chemotherapy has reached a plateau.